Research suggests that inhibiting RAGE signaling may prevent the malignant characteristics of pancreatic ductal adenocarcinoma cells. The role of RAGE in pancreatic cancer appears to involve promoting tumor cell survival and potentially interacting with other factors such as KRAS-mediated hypoxic signaling. The exact mechanisms and pathways involved are being explored, including the potential impact of feedback loops and autophagy on treatment outcomes.